ClinicalTrials.Veeva

Menu

Molecular Mechanisms Underpinning Sarcopenic Obesity

T

The Swedish School of Sport and Health Sciences

Status

Enrolling

Conditions

Aging
Sarcopenic Obesity
Obesity
Sarcopenia

Treatments

Dietary Supplement: Essential amino acids (EAA)

Study type

Observational

Funder types

Other

Identifiers

NCT06120647
2019-04016

Details and patient eligibility

About

The coexistence of obesity and sarcopenia results in sarcopenic obesity, a high-risk geriatric condition associated with metabolic perturbations and several co-morbidities. Despite the rising numbers of older adults diagnosed with sarcopenic obesity, few studies have characterized this condition on the muscle cell and systemic level. This study sought to comprehensively assess the influence of sarcopenic obesity on muscle and blood-related parameters and compare it to non-sarocopenic obese and non-sarcopenic lean older adults.

Enrollment

60 estimated patients

Sex

All

Ages

18 to 80 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Body fat % in accordance with previously defined criteria
  • Free of smoking (since 10 years)
  • Able to walk without assistance
  • Able to perform bilateral leg extension exercise

Exclusion criteria

  • History of or present disease of myocardial, vascular, endocrine, hepatic, renal, pulmonary or neuromuscular origin
  • Uncontrolled hypo/hypertension
  • Use of anticoagulants (Warfarin, Trombyl)
  • Use of metformin or other anti-diabetic medications
  • Poor appetite and unexplained weight loss (4,5 kg) over the past 6 months
  • Active malignancy
  • Present infection
  • Dementia or delirium
  • Other conditions that may interfere with the study protocol in the opinion of the PI

Trial design

60 participants in 4 patient groups

Sarcopenic obesity
Description:
Age: 70-80 years Men, ALM/W \< 25.7 %, body fat % \> 35 Women, ALM/W \< 19.7 %, body fat % \> 40
Treatment:
Dietary Supplement: Essential amino acids (EAA)
Non-sarcopenic obese
Description:
Age: 70-80 years Men, ALM/W \> 25.7 %, body fat % \> 35 Women, ALM/W \> 19.7 %, body fat % \> 40
Treatment:
Dietary Supplement: Essential amino acids (EAA)
Non-sarcopenic lean
Description:
Age: 70-80 years Men, ALM \> 7.0 kg/m2, body fat % \< 25 Women, ALM \> 5.5 kg/m2, body fat % \< 32
Treatment:
Dietary Supplement: Essential amino acids (EAA)
Young lean
Description:
Age: 18-40 years Men, ALM \> 7.0 kg/m2, body fat % \< 25 Women, ALM \> 5.5 kg/m2, body fat % \< 32
Treatment:
Dietary Supplement: Essential amino acids (EAA)

Trial documents
1

Trial contacts and locations

1

Loading...

Central trial contact

William Apró, PhD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems